CLL biomarkers are informative for prognosis and therapy determination.1-4
Some CLL biomarkers are implicated in poor outcomes2-4
Understanding genetic abnormalities in chronic lymphocytic leukemia (CLL) helps inform prognosis and patient care.5 While del 17p—perhaps the best known of these prognostic markers—is associated with poor response and survival in patients, it is present in only about 10% of the CLL population at the time of diagnosis.1,5-9
However, other biomarkers—such as del 11q and unmutated IGHV—occur more frequently in the CLL population and are also associated with poor outcomes.2-4,10
Some other common chromosomal aberrations—such as del 13q and trisomy 12—are associated with either a favorable or neutral prognosis.9
iwCLL and NCCN recommend testing before you treat1,5
Links to expert panel guidelines, patient education materials, and more
CLL=chronic lymphocytic leukemia, del=deletion, FISH=fluorescence in situ hybridization, IGHV=immunoglobulin heavy-chain variable region gene, iwCLL=lnternational Working Group on CLL, NCCN=National Comprehensive Cancer Network.
References: 1. Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745-2760. 2. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94(6):1840‑1847. 3. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig VH genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94(6):1848‑1854. 4. Döhner H, Stilgenbauer S, James MR, et al. 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood. 1997;89(7):2516‑2522. 5. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma V.4.2019. © National Comprehensive Cancer Network, Inc. 2019. All rights reserved. Accessed April 15, 2019. To view the most recent and complete version of the guideline, go online to NCCN.org. 6. Grever MR, Lucas DM, Dewald GW, et al. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US intergroup phase III trial E2997. J Clin Oncol. 2007;25(7):799‑804. 7. Stilgenbauer S, Kröber A, Busch R, et al. 17p deletion predicts for inferior overall survival after fludarabine-based first line therapy in chronic lymphocytic leukemia: first analysis of genetics in the CLL4 trial of the GCLLSG. Blood (ASH Annual Meeting Abstracts). 2005;106(11):Abstract 715. 8. Stilgenbauer S, Zenz T, Winkler D, et al. Genomic aberrations, VH mutation status and outcome after fludarabine and cyclophosphamide (FC) or FC plus rituximab (FCR) in the CLL8 trial. Presented at: 50th Annual ASH Meeting; December 6-9, 2008; San Francisco, CA. Abstract 781. 9. Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343(26):1910‑1916. 10. Parker TL, Strout MP. Chronic lymphocytic leukemia: prognostic factors and impact on treatment. Discov Med. 2011;11(57):115-123.